

Efficacy of oral intra-dialysis supplement in haemodialysis patients with malnutrition

Submission date 06/11/2007	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 27/11/2007	Overall study status Completed	☐ Protocol
Last Edited 28/11/2007	Condition category Nutritional, Metabolic, Endocrine	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Waeel Ibrahim Alkrekshi

Contact details
Avenida Marques de Corbera 6, 6d
Madrid
Spain
28017
+34 91 62 78 88 95 0
krekshi@hotmail.com

Additional identifiers

Protocol serial number
06/178

Study information

Scientific Title

Study objectives

Nutritional support in the form of oral supplement during the sessions of haemodialysis improves the nutritional status of the patients, increases the oral food intake, improves the functional situation and quality of life and reduces the morbidity and mortality.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Ethical Committee of Clinical Investigation of the Hospital Clinico San Carlos on the 24th January 2007 (ref: 1.2/07). Signed by secretary of the committee Dr. M. Garcia Arenillas.

Primary study design

Interventional

Study design

Randomised controlled single-blinded trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Malnutrition

Interventions

Specific oral supplement formula for patients on haemodialysis (Nepro) plus dietetic consultation for the case group, versus only dietetic consultation for the control group. The formula is Nepro, a product of Abbott laboratory. Dosage is 236 ml in each session of haemodialysis, providing 472 kcal and 7 g of protein per 100 ml.

Duration of intervention: 6 months

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

The following data will be collected at the beginning of the study (basal), and at three and six months (final):

1. Serum albumin, measured by blood analysis
2. Prealbumin, measured by blood analysis

Key secondary outcome(s)

Collected at the beginning of the study (basal), collected at the beginning of the study (basal), and at three and six months (final):

1. Prevalence of malnutrition
2. Anthropometric nutritional parameters
3. Analytical nutritional parameters

4. Body composition (collected at the beginning of the study [basal] and at the sixth month [final] only)
5. Quality of life
6. Functional scale
7. Appetite
8. Oral food intake. Later on this information will be passed through a special program in order to calculate the total caloric intake and food composition (protein, carbohydrates and fat including saturated, mono- and poly-unsaturated fat)
9. Hospital admissions (collected as and when these events happen)
10. Mortality (collected as and when these events happen)
11. Morbidity and mortality rate (collected as and when these events happen)

Measurements taken to assess these outcomes will include:

1. Anthropometric measures: dry body weight, Body Mass Index (BMI), Brachial Muscle Circumference (BMC), triceps skin fold
2. Blood tests: Complete Blood Count (CBC), urea prior and post dialysis, creatinine, electrolytes, lipid profile, serum iron, ferritin, vitamin B12, folic acid, Parathyroid Hormone (PTH), calcium, phosphate, vitamin D3, transferrin, albumin, prealbumin, bicarbonate (HCO₃) prior and post dialysis, insulin, fasting blood sugar, Homeostasis Model Assessment (HOMA) index, C-Reactive Protein (CRP)
3. Body composition: electrical Bioimpedance Analysis (BIA) monofrequency
4. Nutritional assessment: SGA and MIS
5. Questionnaires: charlson index, karnofsky scales (evaluated by interviewing each patient and by checking his medical history report at the beginning of the study, third month and sixth month), 36-item Short Form health survey (SF-36) and 8-item Council on Nutrition Appetite Questionnaire (CNAQ)
6. Dietary recall (48 hours): day of dialysis and day off will be collected from patients interview

Completion date

15/05/2008

Eligibility

Key inclusion criteria

1. Patients over 18 years old
2. Maintained haemodialysis (at least 6 months on dialysis)
3. Malnutrition criteria (Subjective Global Assessment [SGA] grade B or C or Malnutrition Inflammation Score [MIS] score greater than 8) and at least two altered analytical parameters (albumin less than 3.7 g/dl, prealbumin less than 30 g/l, total cholesterol less than 200 mg/dL with C-Reactive Protein [CRP] within normal range)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Lack of signed consent
2. Difficulty in understanding Spanish language
3. Patients diagnosed of cancer except skin cancer
4. Patients went through surgical operation in the last three months
5. Patients with Dementia or Alzheimer disease

Date of first enrolment

15/11/2007

Date of final enrolment

15/05/2008

Locations

Countries of recruitment

Spain

Study participating centre

Avenida Marques de Corbera 6, 6d

Madrid

Spain

28017

Sponsor information

Organisation

Foundation of Metabolic Studies (Fundacion de estudios metabolicos) (Spain)

Funder(s)

Funder type

Research organisation

Funder Name

Foundation of Metabolic Studies (Fundacion de estudios metabolicos) (Spain) - in cooperation with the Hospital Clinco San Carlos (Spain), Department of Endocrinology and Nutrition

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration